Home » Healthcare » Non-Alcoholic Steatohepatitis (Nash) Biomarkers Market

Non-Alcoholic Steatohepatitis (Nash) Biomarkers Market By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others) By End-use (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Key Highlights of the Report

The global Non-alcoholic Steatohepatitis (Nash) Biomarkers market is segmented by type, end-use, and region. In 2022, the serum biomarkers segment held the most significant market share at 32.51%. In 2022, the pharma and CRO industry end-use segment held the biggest market share of 40.58% and is predicted to grow at the fastest rate during the forecast period. North America held the most significant market share of 59.53% in 2022.

The increased demand for non-invasive diagnostic approaches for NASH detection and the launch of new diagnostic tests are driving the market growth. The challenges limiting the market growth are a lack of standardization and limited clinical validation.

Collaborations and partnerships among pharmaceutical firms, diagnostic companies, research institutions, and regulatory authorities promote innovation and hasten the development and commercialization of NASH biomarkers in North America. These collaborations pool expertise, resources, and networks to accelerate biomarker discovery, validation, and regulatory approval.

Market Overview

The global market for Non-alcoholic Steatohepatitis (Nash) Biomarkers has steadily risen in recent years and is predicted to increase at a CAGR of 23.10% between 2023 and 2030. The market was worth USD 0.91 billion in 2022 and is predicted to be around USD 3.91 billion by 2030.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

What Are the Most Significant Driving Factors in the Global Non-Alcoholic Steatohepatitis (Nash) Biomarkers Market?

The increased demand for non-invasive diagnostic approaches for NASH detection and the launch of new diagnostic tests are driving the market growth.

What Are the Major Challenges Facing the Global Non-Alcoholic Steatohepatitis (Nash) Biomarkers Market?

The challenges limiting the market growth are a lack of standardization and limited clinical validation.

What Are the Growth Opportunities for the Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market?

The market’s primary opportunities are digital health and remote monitoring, biomarker panels, and multiomics approaches.

Executive Summary

Overview of the Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market

NASH biomarkers offer a non-invasive alternative to the current gold standard for diagnosing NASH, liver biopsy. These techniques reduce the need for invasive procedures by using blood-based or imaging-based biomarkers, decreasing patient discomfort, risks, and costs associated with liver biopsy. NASH biomarkers are important in the identification of patients for clinical trials. They allow researchers to identify and register individuals who are more likely to respond to investigational treatments, improving the likelihood of favorable clinical trial outcomes. Biomarkers are also used as objective indicators to assess treatment efficacy and safety during clinical trials.

Market Definition

The Non-Alcoholic Steatohepatitis (NASH) biomarkers market is the market for diagnostic biomarkers used in detecting, diagnosing, monitoring, and managing NASH. NASH biomarkers are unique molecules or indications discovered in blood, imaging scans, or other biological materials that can provide information regarding the presence, severity, progression, and responsiveness to the therapy of NASH.

Market Insights

The global demand for Non-alcoholic Steatohepatitis (Nash) Biomarkers was valued at USD 0.91 billion in 2022 and is predicted to reach USD 3.91 billion in 2030, rising at a CAGR of 23.10% between 2023 and 2030.
In 2022, the serum biomarkers segment held the most significant market share at 32.51%.
In 2022, the pharma and CRO industry end-use segment held the biggest market share of 40.58% and is predicted to grow at the fastest rate during the forecast period.
North America held the most significant market share of 59.53% in 2022.
During the forecast period, Europe’s market is expected to grow at a profitable rate of 23.51%.
Asia Pacific is expected to be the fastest-growing region in the Non-alcoholic Steatohepatitis (Nash) Biomarkers market.
The increased demand for non-invasive diagnostic approaches for NASH detection and the launch of new diagnostic tests are driving the market growth.
The challenges limiting the market growth are a lack of standardization and limited clinical validation.
The market’s primary opportunities are digital health and remote monitoring, biomarker panels, and multiomics approaches.

Segmentation by Type

In 2022, the serum biomarkers segment held the most significant market share at 32.51%.
The apoptosis biomarkers segment is expected to grow at a 23.64% CAGR during the forecast period.
Other types, such as Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, and Others, also contribute to the demand for Non-alcoholic Steatohepatitis (Nash) Biomarkers.

Segmentation by End-use

In 2022, the pharma and CRO industry end-use segment held the biggest market share of 40.58% and is predicted to grow at the fastest rate during the forecast period.
Other end-use, such as Hospitals, Diagnostic Labs, and Academic Research Institutes, also contribute to the demand for Non-alcoholic Steatohepatitis (Nash) Biomarkers.

Segmentation by Region

North America held the most significant market share of 59.53% in 2022, possibly due to several factors, like increased diagnosis rates and the early launch of innovative products in this region.
During the forecast period, Europe’s market is expected to grow at a profitable rate of 23.51%.
Asia Pacific is expected to be the fastest-growing region in the Non-alcoholic Steatohepatitis (Nash) Biomarkers market.

The rest of the world, including Latin America, the Middle East, and Africa, contributes to the remaining demand for Non-alcoholic Steatohepatitis (Nash) Biomarkers.

The increased demand for Non-alcoholic Steatohepatitis (Nash) Biomarkers can be attributed to the advent of novel diagnostic techniques. However, the market is hindered by Limited Clinical Validation.

Personalized medicine is gaining traction in the NASH biomarkers market in the United States. Biomarkers are being used to adapt treatment regimens for individual patients based on illness features and therapeutic responses. This trend involves the discovery of predictive biomarkers that can aid in selecting the most effective treatment options and the personalized monitoring of treatment response. Offering targeted medicines based on the patient’s needs aims to optimize therapeutic outcomes while minimizing unwanted effects.

Biomarkers are important in the risk classification of NASH patients in Germany. The discovery of biomarkers that can predict disease progression, the development of liver fibrosis, and the likelihood of acquiring advanced liver disease allows healthcare practitioners to deploy resources and interventions more efficiently. For high-risk patients, biomarker-based risk assessment allows personalized treatment strategies and the early commencement of suitable therapies.

The need for non-invasive diagnostic techniques for NASH identification is growing.

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD) that causes inflammation and damage to the liver cells. As the prevalence of NAFLD and NASH increases globally, there is a rising demand for non-invasive diagnostic methods to diagnose and monitor disease development. As a result, the market for non-alcoholic steatohepatitis (NASH) biomarkers has grown.

Obesity, sedentary lifestyles, and poor eating habits have all contributed to an increase in the global incidence of NAFLD and NASH. This has resulted in a significant demand for accurate and non-invasive diagnostic methods for NASH early identification and monitoring.

The demand for precise diagnostic methods to stratify NASH patients based on disease severity and individual response to treatment is increasing as the emphasis on personalized medicine and targeted therapeutics grows. Biomarkers are important in patient selection for clinical trials and monitoring therapy response, which drives the demand for NASH biomarkers.

The introduction of new diagnostic tests

The introduction of new diagnostic tests is a major driver of the Non-Alcoholic Steatohepatitis (NASH) biomarkers industry. These novel diagnostic assays improve the accuracy, sensitivity, and specificity of diagnosing and monitoring NASH, overcoming the limits of traditional diagnostic approaches.

Novel biomarker-based assays use technological and scientific advances to increase diagnostic accuracy. These tests employ specific biomarkers or panels of biomarkers that have been shown to correlate with the existence, severity, or progression of NASH. These tests assist healthcare providers in making more informed decisions about patient management by giving more reliable and precise diagnostic information.

The successful launch and regulatory approval of new diagnostic tests contributes significantly to market growth. Obtaining regulatory clearances, such as approval from the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) in Europe, aids in establishing credibility and promoting market uptake. As additional tests are approved by regulatory bodies, healthcare practitioners and institutions are more likely to incorporate them into clinical practice, driving market growth.

Lack of Standardization

A lack of standardized diagnostic criteria and biomarker panels for NASH hampers the market. The field of NASH biomarkers is growing, and consensus on the most reliable and accurate biomarkers for diagnosis and monitoring is required. Test findings can vary due to the lack of standardized standards, limiting general adoption.

Limited Clinical Validation

Many possible NASH indicators are still in the early phases of development and will require significant clinical testing. Biomarker validation entails large-scale investigations to determine its accuracy, sensitivity, specificity, and connection with disease severity and progression. The scarcity of sufficient clinical validation evidence can hamper biomarker adoption in clinical practice.

Reimbursement Challenges

Reimbursement policies and diagnostic test coverage are critical factors in market acceptance. The reimbursement process for innovative biomarker-based tests can be complicated and time-consuming. The lack of clear funding paths or limited reimbursement coverage can hamper the broad adoption of NASH biomarkers, especially in certain healthcare systems or regions.

Digital Health and Remote Monitoring

Digital health technology, such as wearable devices, mobile applications, and remote monitoring systems, provides new opportunities for NASH biomarker monitoring and disease treatment. Continuous biomarker and disease progression marker monitoring via digital health platforms can enable real-time tracking of NASH and facilitate early intervention and personalized care.

Biomarker Panels and Multiomics Approaches

A rising interest exists in producing biomarker panels incorporating numerous biomarkers or employing multiomics techniques. These panels can give a more thorough and accurate assessment of NASH by evaluating a combination of biomarkers such as genetic, proteomic, metabolomic, and imaging-based indicators. Integrating different data types and technologies can potentially improve diagnostic accuracy, illness staging, and treatment response prediction.

Artificial Intelligence and Machine Learning

The use of artificial intelligence (AI) and machine learning (ML) algorithms in NASH biomarker research has the potential to improve diagnosis accuracy and forecast disease progression. AI and machine learning algorithms can scan enormous datasets, uncover complicated patterns, and build prediction models that improve biomarker data interpretation. In the case of NASH, these technologies can potentially improve risk assessment, treatment response prediction, and personalized medicine methods.

Competitive Landscape

Key Players

The global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is very competitive, with several prominent competitors. The following are some of the top market players and their market shares:

GENFIT
Prometheus Laboratories
Siemens Medical Solutions USA, Inc.
BioPredictive
Quest Diagnostics
AstraZeneca
Exalenz Bioscience Ltd.
Laboratory Corporation of America Holdings
Pfizer, Inc.
Bristol-Myers Squibb Company

These organizations prioritize product innovation, distribution channel expansion, and mergers and acquisitions to stay competitive.

The global Non-alcoholic Steatohepatitis (Nash) Biomarkers market’s key competitors continuously seek to stay ahead by launching new products and technologies.

In 2021, Second Genome and Virginia Commonwealth University collaborated on research to establish a non-invasive composite biomarker for non-alcoholic steatohepatitis based on stool samples.

Gilead Sciences, a leading biotech corporation in the United States, said in September 2020 that a definitive agreement had been reached to acquire immune medicine specialists from antibody-drug conjugate (ADC).

Novo Nordisk A/S stated in November 2020 that it had reached a formal deal to acquire Emisphere Technologies Inc. (Emisphere). This proprietary technology drug delivery business uses Eligen SNAC technology, which allows for oral medicinal formulations.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

The increased demand for non-invasive diagnostic approaches for NASH detection and the launch of new diagnostic tests are driving the market growth.
Market segmented by type, end-use, and region.
In 2022, the serum biomarkers segment held the most significant market share at 32.51%.
In 2022, the pharma and CRO industry end-use segment held the biggest market share of 40.58% and is predicted to grow at the fastest rate during the forecast period.
North America is leading market growth; the market is highly competitive with key players, including GENFIT, Prometheus Laboratories, and Siemens Medical Solutions USA, Inc.

Future Outlook

With the development of novel diagnostic tests, the global Non-alcoholic Steatohepatitis (Nash) Biomarkers market looks bright.
The increased demand for non-invasive diagnostic approaches for NASH detection and the launch of new diagnostic tests are driving the market growth.
The challenges limiting the market growth are a lack of standardization and limited clinical validation.
Key businesses must focus on product innovation, growing market reach, and maintaining competitive pricing to remain competitive.

Segmentation

By Type
- Serum Biomarkers
- Hepatic Fibrosis Biomarkers
- Apoptosis Biomarkers
- Oxidative Stress Biomarkers
- Others
By End-use
- Pharma & CRO Industry
- Hospitals
- Diagnostic Labs
- Academic Research Institutes
By Region

North America
- The US.
- Canada
- Mexico
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market
2.2. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Type
2.3. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By End-use
2.4. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Driver 1
3.2.1.2. Driver 2
3.2.1.3. Driver 3
3.2.2. Market Restraints
3.2.2.1. Restraint 1
3.2.2.2. Restraint 2
3.2.3. Market Opportunities
3.2.3.1. Opportunity 1
3.2.3.2. Opportunity 2
3.2.4. Major Industry Challenges
3.2.4.1. Challenge 1
3.2.4.2. Challenge 2
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Type
3.5.2. End-use
3.5.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Type
7.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Overview, by Type
7.1.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Revenue Share, By Type, 2022 Vs 2030 (in %)
7.2. Serum Biomarkers
7.2.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region, 2017-2030 (US$ Bn)
7.3. Hepatic Fibrosis Biomarkers
7.3.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region, 2017-2030 (US$ Bn)
7.4. Apoptosis Biomarkers
7.4.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region, 2017-2030 (US$ Bn)
7.5. Oxidative Stress Biomarkers
7.5.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region, 2017-2030 (US$ Bn)
7.6. Others
7.6.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region, 2017-2030 (US$ Bn)

8. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By End-use
8.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Overview, by End-use
8.1.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By End-use, 2022 vs 2030 (in %)
8.2. Pharma & CRO Industry
8.2.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region, 2017-2030 (US$ Bn)
8.3. Hospitals
8.3.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region, 2017-2030 (US$ Bn)
8.4. Diagnostic Labs
8.4.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region, 2017-2030 (US$ Bn)
8.5. Academic Research Institutes
8.5.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region, 2017-2030 (US$ Bn)

9. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region
9.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Overview, by Region
9.1.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Region, 2022 vs 2030 (in%)
9.2. Type
9.2.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By Type, 2017-2030 (US$ Bn)
9.3. End-use
9.3.1. Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, By End-use, 2017-2030 (US$ Bn)

10. North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Analysis
10.1. North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2030(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2017-2030 (US$ Bn)
10.3.1. North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2022 Vs 2030 (in%)
10.3.2. U.S.
10.3.2.1. U.S. Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.2.2. U.S. Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
10.3.2.3. U.S. Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
10.3.3. Canada
10.3.3.1. Canada Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.3.2. Canada Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
10.3.3.3. Canada Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
10.3.4. Mexico
10.3.4.1. Mexico Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.4.2. Mexico Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
10.3.4.3. Mexico Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)

11. Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Analysis
11.1. Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2017-2030 (US$ Bn)
11.3.1. Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2022 Vs 2030 (in%)
11.3.2. Germany
11.3.2.1. Germany Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.2.2. Germany Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
11.3.2.3. Germany Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
11.3.3. France
11.3.3.1. France Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.3.2. France Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
11.3.3.3. France Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
11.3.4. UK
11.3.4.1. UK Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.4.2. UK Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
11.3.4.3. UK Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
11.3.5. Italy
11.3.5.1. Italy Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.5.2. Italy Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
11.3.5.3. Italy Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
11.3.6. Spain
11.3.6.1. Spain Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.6.2. Spain Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
11.3.6.3. Spain Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
11.3.7. Rest of Europe
11.3.7.1. Rest of Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.7.2. Rest of Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
11.3.7.3. Rest of Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)

12. Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Analysis
12.1. Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2017-2030 (US$ Bn)
12.3.1. Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2022 Vs 2030 (in%)
12.3.2. China
12.3.2.1. China Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.2.2. China Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
12.3.2.3. China Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
12.3.3. Japan
12.3.3.1. Japan Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.3.2. Japan Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
12.3.3.3. Japan Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
12.3.4. India
12.3.4.1. India Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.4.2. India Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
12.3.4.3. India Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
12.3.5. South Korea
12.3.5.1. South Korea Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.5.2. South Korea Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
12.3.5.3. South Korea Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
12.3.6. South-East Asia
12.3.6.1. South-East Asia Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.6.2. South-East Asia Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
12.3.6.3. South-East Asia Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
12.3.7. Rest of Asia Pacific
12.3.7.1. Rest of Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.7.2. Rest of Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
12.3.7.3. Rest of Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)

13. Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Analysis
13.1. Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2017-2030 (US$ Bn)
13.3.1. Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2022 Vs 2030 (in%)
13.3.2. Brazil
13.3.2.1. Brazil Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.2.2. Brazil Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
13.3.2.3. Brazil Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
13.3.3. Argentina
13.3.3.1. Argentina Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.3.2. Argentina Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
13.3.3.3. Argentina Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
13.3.4. Rest of Latin America
13.3.4.1. Rest of Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.4.2. Rest of Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
13.3.4.3. Rest of Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)

14. Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Analysis
14.1. Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2017-2030 (US$ Bn)
14.3.1. Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2022 Vs 2030 (in%)
14.3.2. GCC Countries
14.3.2.1. GCC Countries Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.2.2. GCC Countries Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
14.3.2.3. GCC Countries Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
14.3.3. South Africa
14.3.3.1. South Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.3.2. South Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
14.3.3.3. South Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)
14.3.4. Rest of Middle East and Africa
14.3.4.1. Rest of Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.4.2. Rest of Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers, By Type, 2017-2030 (US$ Bn)
14.3.4.3. Rest of Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers, By End-use, 2017-2030 (US$ Bn)

15. Company Profiles
15.1. GENFIT
15.1.1. Company Overview
15.1.2. Product /Services Portfolio
15.1.3. Geographical Presence
15.1.4. Financial Summary
15.1.4.1. Market Revenue and Net Profit (2019-2022)
15.1.4.2. Business Segment Revenue Analysis
15.1.4.3. Geographical Revenue Analysis
15.2. Prometheus Laboratories
15.3. Siemens Medical Solutions USA, Inc.
15.4. BioPredictive
15.5. Quest Diagnostics
15.6. AstraZeneca
15.7. Exalenz Bioscience Ltd.
15.8. Laboratory Corporation of America Holdings
15.9. Pfizer, Inc.
15.10. Bristol-Myers Squibb Company

List of Figures
FIG. 1 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Segmentation
FIG. 4 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2022 (US$ Bn)
FIG. 5 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2022 (US$ Bn)
FIG. 6 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Geography, 2022 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by Type, 2022
FIG. 8 Attractive Investment Proposition, by End-use, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Manufacturers, 2022
FIG. 12 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Value Contribution, By Type, 2022 & 2030 (Value %)
FIG. 13 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Serum Biomarkers, Value, 2017-2030 (US$ Bn)
FIG. 14 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Hepatic Fibrosis Biomarkers, Value, 2017-2030 (US$ Bn)
FIG. 15 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Apoptosis Biomarkers, Value, 2017-2030 (US$ Bn)
FIG. 16 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Oxidative Stress Biomarkers, Value, 2017-2030 (US$ Bn)
FIG. 17 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Others, Value, 2017-2030 (US$ Bn)
FIG. 18 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market Value Contribution, By End-use, 2022 & 2030 (Value %)
FIG. 19 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Pharma & CRO Industry, Value, 2017-2030 (US$ Bn)
FIG. 20 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Hospitals, 2017-2030 (US$ Bn)
FIG. 21 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Diagnostic Labs, 2017-2030 (US$ Bn)
FIG. 22 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Academic Research Institutes, 2017-2030 (US$ Bn)
FIG. 23 North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 24 U.S. Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 25 Canada Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 26 Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 27 Germany Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 28 France Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 29 U.K. Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 30 Italy Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 31 Spain Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 32 Rest of Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 33 Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 34 China Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 35 Japan Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 36 India Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 37 South Korea Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 38 South-East Asia Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 39 Rest of Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 40 Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 41 Brazil Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 42 Mexico Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 43 Rest of Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 44 Middle East & Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 45 GCC Countries Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 46 South Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 47 Rest of Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market
TABLE 2 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market: Market Drivers Impact Analysis
TABLE 3 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market: Market Restraints Impact Analysis
TABLE 4 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Competitive Benchmarking, 2022
TABLE 5 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Key Strategies Analysis, 2022
TABLE 7 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Serum Biomarkers, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Serum Biomarkers, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Hepatic Fibrosis Biomarkers, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Hepatic Fibrosis Biomarkers, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Apoptosis Biomarkers, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Apoptosis Biomarkers, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Oxidative Stress Biomarkers, By Region, 2017-2022 (US$ Bn)
TABLE 14 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Oxidative Stress Biomarkers, By Region, 2023-2030 (US$ Bn)
TABLE 15 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 16 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 17 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Pharma & CRO Industry, By Region, 2017-2022 (US$ Bn)
TABLE 18 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Pharma & CRO Industry, By Region, 2023-2030 (US$ Bn)
TABLE 19 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Hospitals, By Region, 2017-2022 (US$ Bn)
TABLE 20 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Hospitals, By Region, 2023-2030 (US$ Bn)
TABLE 21 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Diagnostic Labs, By Region, 2017-2022 (US$ Bn)
TABLE 22 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Diagnostic Labs, By Region, 2023-2030 (US$ Bn)
TABLE 23 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Academic Research Institutes, By Region, 2017-2022 (US$ Bn)
TABLE 24 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Academic Research Institutes, By Region, 2023-2030 (US$ Bn)
TABLE 25 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 26 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 27 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 28 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 29 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Region, 2017-2022 (US$ Bn)
TABLE 30 Global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Region, 2023-2030 (US$ Bn)
TABLE 31 North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 32 North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 33 North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 34 North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 35 North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2017-2022 (US$ Bn)
TABLE 36 North America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2023-2030 (US$ Bn)
TABLE 37 United States Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 38 United States Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 39 United States Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 40 United States Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 41 Canada Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 42 Canada Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 43 Canada Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 44 Canada Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 45 Mexico Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 46 Mexico Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 47 Mexico Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 48 Mexico Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 49 Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 50 Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 51 Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 52 Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 53 Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2017-2022 (US$ Bn)
TABLE 54 Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Country, 2023-2030 (US$ Bn)
TABLE 55 Germany Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 56 Germany Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 57 Germany Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 58 Germany Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 59 France Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 60 France Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 61 France Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 62 France Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 63 United Kingdom Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 64 United Kingdom Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 65 United Kingdom Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 66 United Kingdom Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 67 Italy Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 68 Italy Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 69 Italy Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 70 Italy Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 71 Spain Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 72 Spain Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 73 Spain Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 74 Spain Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 75 Rest of Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 76 Rest of Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 77 Rest of Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 78 Rest of Europe Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 79 Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 80 Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 81 Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 82 Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 83 China Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 84 China Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 85 China Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 86 China Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 87 Japan Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 88 Japan Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 89 Japan Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 90 Japan Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 91 India Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 92 India Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 93 India Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 94 India Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 95 South Korea Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 96 South Korea Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 97 South Korea Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 98 South Korea Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 99 South-East Asia Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 100 South-East Asia Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 101 South-East Asia Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 102 South-East Asia Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 103 Rest of Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 104 Rest of Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 105 Rest of Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 106 Rest of Asia Pacific Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 107 Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 108 Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 109 Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 110 Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 111 Brazil Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 112 Brazil Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 113 Brazil Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 114 Brazil Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 115 Argentina Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 116 Argentina Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 117 Argentina Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 118 Argentina Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 119 Rest of Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 120 Rest of Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 121 Rest of Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 122 Rest of Latin America Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 123 Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 124 Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 125 Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 126 Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 127 GCC Countries Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 128 GCC Countries Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 129 GCC Countries Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 130 GCC Countries Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 131 South Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 132 South Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 133 South Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 134 South Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)
TABLE 135 Rest of Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 136 Rest of Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 137 Rest of Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2017-2022 (US$ Bn)
TABLE 138 Rest of Middle East and Africa Non-alcoholic Steatohepatitis (Nash) Biomarkers Market, by End-use, 2023-2030 (US$ Bn)

Frequently Asked Questions

What is the current global market size for Non-alcoholic Steatohepatitis (Nash) Biomarkers?

In 2022, the global Non-alcoholic Steatohepatitis (Nash) Biomarkers market was estimated to be worth USD 0.91 billion.

What will be the growth rate of the Non-alcoholic Steatohepatitis (Nash) Biomarkers market between 2023 and 2030?

The Non-alcoholic Steatohepatitis (Nash) Biomarkers market is estimated to grow at a 23.10% CAGR between 2023 and 2030, reaching USD 3.91 billion in 2030.

Which segment is leading the market share in terms of type?

In 2022, the serum biomarkers segment held the most significant market share at 32.51%.

Which segment is leading the market share in terms of end-use?

In 2022, the pharma and CRO industry end-use segment held the biggest market share of 40.58% and is predicted to grow at the fastest rate during the forecast period.

Which segments are covered in the global Non-alcoholic Steatohepatitis (Nash) Biomarkers Market report?

The global Non-alcoholic Steatohepatitis (Nash) Biomarkers market research report is divided into the following categories: By Type, By End-use

Which region is driving the Non-alcoholic Steatohepatitis (Nash) Biomarkers market?

North America held the most significant market share of 59.53% in 2022.

Who are the key participants in the global Non-alcoholic Steatohepatitis (Nash) Biomarkers market?

The top players include GENFIT, Prometheus Laboratories, and Siemens Medical Solutions USA, Inc. Other major players include BioPredictive, Quest Diagnostics, and AstraZeneca.

What are the most important market drivers for Non-alcoholic Steatohepatitis (Nash) Biomarkers?

The increased demand for non-invasive diagnostic approaches for NASH detection and the launch of new diagnostic tests are driving market growth.

What are the biggest market restraints in the Non-alcoholic Steatohepatitis (Nash) Biomarkers industry?

The challenges limiting the market growth are a lack of standardization and limited clinical validation.

What are the most important market opportunities for Non-alcoholic Steatohepatitis (Nash) Biomarkers?

The market’s primary opportunities are digital health and remote monitoring, biomarker panels, and multiomics approaches.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –